



DBMSS



EHA&EuroBloodNet Spotlight Session 3: Idiopathic multicentric Castleman Disease (iMCD)



### Simone Ferrero, MD

University of Torino, Italy, EU

15.02.2022







EUROPEAN

HEMATOLOGY ASSOCIATION



Network Hematological Diseases (ERN EuroBloodNet)







# Main discussion points about iMCD

- ✓ Clinical phenotypes of the disease
- ✓ Differential diagnosis
- ✓ Relationship with TAFRO, IgG4RD, and POEMS
- ✓ Pathophysiology
- ✓ Treatment



Hematological Diseases (ERN EuroBloodNet)

Network for rare or low prevalence complex diseases







# **DISCLOSURES: Simone Ferrero**

- Janssen: consultancy, advisory board, reasearch support, speakers honoraria
- **EUSA Pharma**: consultancy, advisory board, speakers honoraria
- Morphosys, Gilead: reasearch support
- Incyte, Clinigen: advisory board
- Servier, Gentili: speakers honoraria



Hematological Diseases (ERN EuroBloodNet)





# **Case presentation**

- 50-years-old Caucasian male with Fever of Unknown Origin (FUO) persisting for one month.
- He daily presented fever till 39.5 °C, associated with nocturnal diaphoresis, asthenia and chills.

### Laboratory results

- Blood count: mild anemia (11 g/dL), normal platelet count (250 k/mL) and leukocytosis (12800 /mL) with neutrophilia and monocytosis
- Inflammation markers were elevated (CRP 132 mg/L, ESR 89 mm/h)
- Slight hypoalbuminemia (3.4 g/dL).
- Blood culture and serological tests excluded infections.




ow prevalence

seases (FRN EuroBloodNet)



#### CASE REPORT



Simone Ferrero<sup>1,2\*</sup><sup>1,2</sup> and Simone Ragaini<sup>1,2</sup>

Journal of Medical Case Reports (2021) 15:105





Open Acces


## **Case presentation**

### **CT-PET** scan

Evidence of contrast-enhancing, peri-pancreatic (short axis diameter 10 mm) and retrocaval adenopathies (maximum size 16 x 11 mm) with maximum SUV of 7.1

### **Bone marrow biopsy**

- Non-necrotizing epithelioid granulomas
- Excess of interstitial and perivascular polyclonal plasma cells (about 15%).



Ferrero, S. J Med Case Reports, 2021





Diseases (ERN EuroBloodNet)





# **Case presentation**


### Lymph node biospy

- Vascular plasma cells proliferation and expansion along with focal aspects of follicular regression
- Compatible diagnosis of "HHV-8/HIV negative iMCD, of uncertain histopathological classification", thus neither clearly attributable to the Hyalino Vascular, nor Plasmacytic nor Mixed subtype.



seases (FRN EuroBloodNet)






### Epidemiology and treatment patterns of idiopathic multicentric Castleman **6** blood advances disease in the era of IL-6-directed therapy



Sudipto Mukherjee, Rabecka Martin,<sup>2</sup> Brenda Sande,<sup>2</sup> Jeremy S. Paige,<sup>3</sup> and David C. Fajgenbaum<sup>4</sup>

<sup>1</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; <sup>2</sup>EUSA Pharma, Burlington, MA; <sup>3</sup>Eversana, LLC, Milwaukee, WI; and <sup>4</sup>Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

- The epidemiology of CD and, more specifically, iMCD in the United States and worldwide remains poorly understood.
- After the introduction of a CD-specific ICD and publication of international evidence-based diagnostic criteria, it is more feasible to obtain more accurate population estimates.
- Patients with a CD-specific ICD-10 code between 1 January 2017 and 31 December 2019 were included in this analysis.



### Epidemiology and treatment patterns of idiopathic multicentric Castleman **6** blood advances disease in the era of IL-6-directed therapy



Sudipto Mukherjee, Rabecka Martin,<sup>2</sup> Brenda Sande,<sup>2</sup> Jeremy S. Paige,<sup>3</sup> and David C. Fajgenbaum<sup>4</sup>

<sup>1</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; <sup>2</sup>EUSA Pharma, Burlington, MA; <sup>3</sup>Eversana, LLC, Milwaukee, WI; and <sup>4</sup>Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

- iMCD incidence was estimated to be **3.4 per million** in 2017 and 3.1 (95% CI, 1.2 2 10.0) per million ٠ in 2018.
- iMCD prevalence was estimated to be 6.9 per million in 2017 and 9.7 (95% CI, 5.6-17.8) per million ۲ in 2018.

#### Table 3. Annual incidence and prevalence from 2017 to 2018

	All CD		UCD		MCD		HHV-8-MCD		iMCD	
	Cases per	Total	Cases	Total US	Cases	Total	Cases	Total	Cases	Total US
	million	US cases	per million	cases	per million	US cases	per million	US cases	per million	cases
Incidence										
2017	5.5	1804	1.9	612	4	1303	0.4	141	3.4	1111
	(2.8-11.5)	(928-3768)	(0.7-5.5)	(239-1804)	(1.71-9.9)	(560-3250)	(0.1-1.6)	(44-514)	(1.4-9.2)	(440-2996)
2018	5.8	1904	2.5	800	3.7	1213	0.6	193	3.1	1022
	(3.0-12.9)	(994-4216)	(0.9-7.9)	(307-2572)	(1.57-10.7)	(513-3503)	(0.1-3.1)	(39-1027)	(1.2-10.0)	(405-3274)
Prevalence										
2017	10.2	3326	2.7	894	7.7	2504	0.7	235	6.9	2246
	(6.2-17.3)	(2034-5671)	(1.2-6.6)	(409-2174)	(4.3-14.3)	(1407-4675)	(0.2-3.1)	(65-1024)	(3.7-13.3)	(1223-4348)
2018	16.2	5282	5.1	1653	11	3613.4	1.2	395	9.7	3172
	(10.5-25.6)	(3450-8385)	(2.6-11.2)	(855-3662)	(6.6-19.5)	(2154-6381)	(0.4-4.3)	(131-1407)	(5.6-17.8)	(1820-5835)

# **iMCD** clinical presentation

### Signs and symptoms

- Lymphadenopathy
- Symptoms B
- Hepatosplenomegaly
- Pleural effusion, anasarca, ascites
- Severe cases with important generalized inflammation status and organ failure
- Skin involvement (cherry hemangioma)

### Laboratory abnormalities

- Elevation of inflammatory indices (ESR, PCR, IL-6, VEGF)
- Hypoalbuminemia, hypergammaglobulinemia, proteinuria
- Anemia, thrombocytosis, or thrombocytopenia
- Autoantibodies (anti-erythrocytes, anti-platelets)



or rare or low prevalence omplex diseases

Diseases (ERN EuroBloodNet)







## **iMCD recommended work-up**



2018 132: 2115-2124 doi:10.1182/blood-2018-07-862334 originally published online September 4, 2018

Purpose	Tests
Inflammatory response	CBC, renal function, liver function, CRP, ESR, fibrinogen, immunoglobulins & free light chains, albumin, ferritin*
Histopathology	Hypervascular/mixed cellularity/ plasmacytic variant
Virologic status	HIV serology, HHV-8 qPCR (peripheral blood), EBER (lymph node), LANA-1 (lymph node)
Cytokine profile	IL-6, VEGF, sIL-2 receptor†
Imaging	CT-PET or CT neck, chest, abdomen, pelvis
Bone marrow evaluation	MGUS, myeloma, reticulin fibrosis
Immunology	ANA, rheumatoid factor
Organ function	ECHO, pulmonary function



Network Hematological Diseases (ERN EuroBloodNet)

for rare or low prevalence complex diseases





## **iMCD** histological presentation

- 1. Three types of histological model:
  - 1. Hypervascular
  - 2. Plasmacytic
  - 3. Mixed
- 2. Other features include:
  - The expanded mantle surrounding the CGs with "onion skin" appearance;
  - 2. Vessels penetrating GCs with a "lollipop" appearance;
  - 3. "budding" follicles
- 3. Subtypes may alternate in subsequent biopsies or may be present at the same time at different sites in the same patient.



Network for rare or low prevalence complex diseases

Hematological Diseases (ERN EuroBloodNet)






Figure from Fajgenbaum, D. C. et al, Blood, 2017



### iMCD diagnostic criteria

#### Inclusion diagnostic criteria for iMCD

David C. Fajgenbaum, Thomas S. Uldrick, Adam Bagg, Dale Frank, David Wu, Gordan Srkalovic, David Simpson, Amy Y. Liu, David Menke, Shanmuganathan Chandrakasan, Mary Jo Lechowicz, Raymond S. M. Wong, Sheila Pierson, Michele Paessler, Jean-François Rossi, Makoto Ide, Jason Ruth, Michael Croglio, Alexander Suarez, Vera Krymskaya, Amy Chadburn, Gisele Colleoni, Sunita Nasta, Raj Jayanthan, Christopher S. Nabel, Corey Casper, Angela Dispenzieri, Alexander Fosså, Dermot Kelleher, Razelle Kurzrock, Peter Voorhees, Ahmet Dogan, Kazuyuki Yoshizaki, Frits van Rhee, Eric Oksenhendler, Elaine S. Jaffe, Kojo S. J. Elenitoba-Johnson, Megan S. Lim

I. Major Criteria (need both):

1. Histopathologic lymph node features consistent with the iMCD spectrum

2. Enlarged lymph nodes ( $\geq$  1 cm in short-axis diameter) in  $\geq$  2 lymph node stations

II. Minor Criteria (need at least 2 of 11 criteria with at least 1 laboratory criterion)

#### Laboratory\*

- 1. Elevated CRP (>10 mg/L) or ESR (>15 mm/h)
- 2. Anemia (hemoglobin < 12.5 g/dL for males, hemoglobin < 11.5 g/dL for females)
- 3. Thrombocytopenia (platelet count < 150 k/mL) or thrombocytosis (platelet count > 400 k/mL)
- 4. Hypoalbuminemia (albumin < 3.5 g/dL)
- 5. Renal dysfunction (eGFR < 60 mL/min/1.73m2) or proteinuria (> 150 mg/2 h or > 10 mg/100 ml)
- 6. Polyclonal hypergammaglobulinemia (total g globulin or immunoglobulin G > 1700 mg/dL)

#### Clinical

- 1. Constitutional symptoms: night sweats, fever (>38°C), weight loss, or fatigue
- 2. Large spleen and/or liver
- 3. Fluid accumulation: edema, anasarca, ascites, or pleural effusion
- 4. Eruptive cherry hemangiomatosis or violaceous papules
- 5. Lymphocytic interstitial pneumonitis

Select additional features supportive of, but not required for diagnosis

Elevated IL-6, sIL-2R, VEGF, IgA, IgE, LDH, and/or B2M

Diagnosis of other disorders that have been associated with iMCD

Reticulin fibrosis of bone marrow (particularly in patients with TAFRO syndrome)

 Both major criteria and at least 2 out of 11 minor criteria (including at least 1 laboratory abnormality) must be met

 All diseases reported in the exclusion criteria must be excluded

#### Exclusion diagnostic criteria for iMCD

Infection-related disorders Autoimmune/autoinflammatory diseases Malignant/lymphoproliferative disorders Malignant/lymphoproliferative disorders

Diagnostic criteria for HHV-8negative/idiopathic multicentric Castleman disease (iMCD). Adapted from Fajgenbaum, D. C. et al, Boold, 2018



#### CLINICAL TRIALS AND OBSERVATIONS | MARCH 23, 2017

#### International, evidence-based consensus diagnostic criteria for HHV-8negative/idiopathic multicentric Castleman disease

#### U Clinical Trials & Observations



## **iMCD** severity

 To be defined as a "severe" MCI, at least 2 of the 5 established criteria must be present

### Severe iMCD

### • ECOG $\ge 2$

- Stage IV renal dysfunction (eGFR < 30; Creatinine >3.0)
- Anasarca and/or ascites and/or pleural/pericardial effusion (effects of hypercytokinemia/low albumin)
- Hemoglobin ≤ 8.0g/dL
- Pulmonary involvement /interstitial pneumonitis w/dyspnea

*Frits van Rhee, International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 2018* 



NETWORK for rare or low prevalence complex diseases

Hematological Diseases (ERN EuroBloodNet)






# <u>\_</u>

# **iMCD correlated diseases**

- Patients with MCI have a <u>prevalence of neoplasms three</u> <u>times higher than healthy controls</u>. However, the relationship between MCI and neoplasms remains unclear.
- 2. <u>TAFRO syndrome</u> may or may not be associated with MCI
- **3.** <u>IgG4-related disease</u> is frequently seen in patients with idiopathic Castleman disease (ICM) but is not a criterion for exclusion.
- 4. <u>POEMS syndrome</u> is often observed in association with MCI, it can be considered the result of cytokine storm triggered by neoplastic plasma cells.



David C. Fajgenbaum, International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease. *Blood* 2017





Network for rare or low prevalence complex diseases

iseases (FRN EuroBloodNet)






# **TAFRO syndrome vs iMCD**




- 57 years old male
- Medical history: diabetes type 2, hypertension, cholecystectomy after previous cholecystits
- Hospitalization for abdominal pain, vomit, fever, dyspnea, and declivous oedemas:





## **TAFRO syndrome**

- Thrombocytopenia
- Ascites
- Reticulin **F**ibrosis
- Renal dysfunction
- Organomegaly



TAFRO		IPL/
Syndrome		non-TAFRO
Hyaline Vascu	lar/Mixed Histopathology	
Thrombocyto	penia	
Severe Anasa	rca	
Myelofibrosis		
<del>&lt;</del>		
←	Renal dysfunction	2 2
<	— Hepatosplenomegaly —	
		Thrombocytosi
	Hypergamr	maglobulinemi
	Plasmacytic/Mixed	Histopatholog

.



Network Hematological Diseases (ERN EuroBloodNet)

Network for rare or low prevalence complex diseases







## **IgG4 related-disease**

- <u>"Fibro-inflammatory" disease</u> with tumefactive (puffy) inflammatory infiltrates and fibrosis mainly of for glandular tissue
- Classical presentation with <u>autoimmune</u> <u>pancreatitis</u>, <u>orbital disease and major</u> <u>salivary gland involvement</u>
- Multicentric Castleman disease-like morphologic subtype (preserved nodal architecture with patent sinusoids and hyperplastic follicles; abundant mature plasma cells in interfollicular areas with some eosinophils).




A Network

Hematological Diseases (ERN EuroBloodNet)


Network for rare or low prevalence complex diseases





## **POEMS** syndrome

- Paraneoplastic syndrome
- Clinical presentation:
  - Polyneuropathy
  - Organomegaly
  - Endocrinopathy
  - Monoclonal immunoglobulin spike
  - **S**kin changes
- MCD can co-occur with POEMS
- Castleman disease is a major criterion in the diagnosis of POEMS syndrome.



Dispenzieri A. POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2019.





Network for rare or low prevalence complex diseases

Hematological Diseases (ERN EuroBloodNet)





Idiopathic multicentric Castleman Disease (iMCD)	POEMS-MCD	iMCD-TAFRO	iMCD-NOS
<b>POEMS syndrome</b> The diagnosis of POEMS syndrome in a patient with MCD	Multiple lymph nodes and tissues	Multiple lymph nodes and tissues	Multiple lymph nodes and tissues
requires both polyneuropathy and monoclonal plasma cell proliferative disorder along with at least one of (Dispenzieri A,Am J Hematol. 2019):	Multiple lymphadenopathies (peripheral and central); monoclonal plasma cell disorder; anaemia	Multiple lymphadenopathies (peripheral and central, often of small volume); thrombocytopenia; anaemia	Multiple lymphadenopathies; thrombocytosis; anaemia
<ul> <li>Organomegaly</li> <li>Extravascular volume overload</li> </ul>	Fever; night sweats; anasarca; weight loss	Fever; night sweats; anasarca; weight loss	Fever; night sweats; anasarca; weight loss
Endocrinopathy	Hepatomegaly; splenomegaly	Hepatomegaly; splenomegaly	Hepatomegaly; splenomegaly
Skin changes	Polyneuropathy;	Renal dysfunction;	Renal dysfunction;
Papilledema	endocrinopathy; skin changes	liver dysfunction	liver dysfunction
<ul> <li>Thrombocytosis or polycythemia</li> <li>European Reference Network for rare or low prevalence</li> </ul>	Plasma cell type: interfollicular mature plasmacytosis; hyaline vascular type: rich intraperi- follicular vascularity	Plasma cell type: interfollicular mature plasmacytosis; hyaline vascular type: rich intraperi- follicular vascularity	Plasma cell type: interfollicular mature plasmacytosis; hyaline vascular type: rich intraperi- follicular vascularity
Complex diseases     Association     Hematological     Diseases (ERN EuroBloodNet)	Table retrieved and adapte	d from Carbone A, Nat Rev	Dis Primers. 2021



#### Pathogenic Significance of Interleukin-6 (IL-6/BSF-2) in Castleman's Disease

By Kazuyuki Yoshizaki, Tadashi Matsuda, Norihiro Nishimoto, Taro Kuritani, Lee Taeho, Katsuyuki Aozasa, Tatsutoshi Nakahata, Hiroshi Kawai, Hiromi Tagoh, Toshihisa Komori, Susumu Kishimoto, Toshio Hirano, and Tadamitsu Kishimoto



- In 1986, the authors examined **2 patients with plasma cell variant Castleman disease**
- IL-6 was quantified in the culture supernatants of lymph node blocks taken from each of the 2 patients as well as in swollen lymph node blocks taken from noninflammatory controls: **IL-6 levels were elevated in both patients compared with the controls**
- After resecting the enlarged lymph node from each patient, all abnormal findings in patient 1 disappeared with a marked reduction in serum IL-6 levels.
- On the other hand, in **patient 2**, symptoms and elevated serum IL-6 levels, **persisted** after surgical removal of the enlarged lymph node

	Before	Affected				Immunoglobulins					
Patient	and After	Lymph	Clinical	Hb	ESR	lgG	lgA	lgM	lgE	CRP	IL-6
(Age, Sex)	Surgery	Nodes	Symptoms	(g/dL)	(mm/h)	(mg/dL)	(mg/dL)	(mg/dL)	(U/mL)	(mg/dL)	(pg/mL)
1 (14, F)	Before	Solitary	(+)	9.1	157	4350	468	332	12	20.70	110
	After (2 wk)	No	(-)	11.6	22	2471	190	253	9	0.05	ND
	After (4 mo)	No	(-)	12.9	6	1813	165	246	ND	0.04	30
2 (52, F)	Before	Multiple	(+)	10.1	138	4650	1040	180	19,900	5.80	70
	After (1 mo)	Multiple	(+)	9.0	144	5320	941	179	ND	5.70	ND
	After (4 mo)	Multiple	(+)	8.2	144	4280	832	163	13,200	12.40	68

Table retrieved from Yoshizaki K, The Role of Interleukin-6 in Castleman Disease, Hematology/Oncology Clinics of North America, 2018



### The cytokine and chemokine storm

Regardless of the etiology, the cytokine

and chemokine storm is the common

pathway that results in the subsequent


clinical and histopathological features of

iMCD.

## HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy

David C. Fajgenbaum,<sup>1</sup> Frits van Rhee,<sup>2</sup> and Christopher S. Nabel<sup>3</sup>


<sup>1</sup>Center for Orphan Disease Research and Therapy, Raymond and Ruth Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; <sup>2</sup>Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and <sup>3</sup>Department of Medicine, Raymond and Ruth Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA





The autoimmune and autoinflammatory hypotheses

- Auto-antibodies triggering proinflammatory cytokine release by antigen-presenting cells that induce the as-yet-unknown hypercytokine-secreting cell to release IL-6
- Dysregulated signaling in an antigen presenting cell releasing IL-6 or other pathologic cytokines
- A defect in the regulation of activated inflammatory cells. The cytokine and chemokine storm is perpetuated by positive feedback of IL-6, other pathologic cytokines, and/or possibly further auto-antibody stimulation.




<sup>1</sup>Center for Orphan Disease Research and Therapy, Raymond and Ruth Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; <sup>2</sup>Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and <sup>3</sup>Department of Medicine, Raymond and Ruth Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA



The paraneoplastic syndrome hypothesis

- A somatic mutation in benign or malignant cells inside or outside of the lymph node causes constitutive cytokine release.
- Preliminary data suggest these may be **lymph node stromal cells**.



Ruth Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA



Network Hematological Diseases (ERN EuroBloodNet)



### The pathogen hypothesis


- Involves either infection with HHV-8 that is clinically undetectable, a novel virus, or another pathogen signaling proinflammatory cytokines.
- An active infection by a single virus is less likely based on preliminary data generated from pathogen discovery studies.



for rare or low prevalence complex diseases

Hematological Diseases (ERN EuroBloodNet)








## **iMCD** treatment

③ Network



# <u>\_\_\_\_\_\_</u>

## **iMCD treatment**




Figure from Treatment of Idiopathic Castleman Disease, Frits van Rhee, Hematology/Oncology Clinics, 2018



Network Hematological Diseases (ERN EuroBloodNet)


for rare or low prevalence complex diseases





### Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

Frits van Rhee, Raymond S Wong, Nikhil Munshi, Jean-Francois Rossi, Xiao-Yan Ke, Alexander Fosså, David Simpson, Marcelo Capra, Ting Liu, Ruey Kuen Hsieh, Yeow Tee Goh, Jun Zhu, Seok-Goo Cho, Hanyun Ren, James Cavet, Rajesh Bandekar, Margaret Rothman, Thomas A Puchalski, Manjula Reddy, Helgi van de Velde, Jessica Vermeulen, Corey Casper



THE LANCET Oncology Lancet Oncol 2014: 15: 966-74



- Double-blind, placebo-controlled study
- Enrolled iMCD patients
- Patients were randomly assigned (2:1) to siltuximab (11 mg/kg intravenous infusion every 3 weeks) or placebo.
- Patients continued treatment until treatment failure.
- The primary endpoint was durable tumour and symptomatic response for at least 18 weeks for the intention-totreat population



### Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial


THE LANCET Oncology Lancet Oncol 2014; 15: 966-74



#### Table of adverse events

	Siltuximab (n=53)	group	Placebo group (n=20	
	All grades	Grade ≥3	All grades	Grade ≥3
Patients with ≥1 adverse event	53 (100%)	25 (47%)	25 (96%)	14 (54%)
Pruritus	22 (42%)	0 (0%)	3 (12%)	0 (0%)
Upper respiratory tract infection	19 (36%)	0 (0%)	4 (15%)	1(4%)
Fatigue	18 (34%)	5 (9%)	10 (38%)	1 (4%)
Maculopapular rash	18 (34%)	0 (0%)	3 (12%)	0 (0%)
Peripheral oedema	17 (32%)	1 (2%)	6 (23%)	0 (0%)
Malaise	15 (28%)	0 (0%)	5 (19%)	0 (0%)
Dyspnoea	13 (25%)	1 (2%)	9 (35%)	1 (4%)
Peripheral sensory neuropathy	13 (25%)	0 (0%)	5 (19%)	1(4%)
Diarrhoea	12 (23%)	0 (0%)	5 (19%)	1(4%)
Localised oedema	11 (21%)	2 (4%)	1(4%)	0 (0%)
Weight gain	11 (21%)	2 (4%)	0 (0%)	0 (0%)
Hyperhidrosis	10 (19%)	2 (4%)	4 (15%)	0 (0%)
Decreased appetite	9 (17%)	1 (2%)	4 (15%)	0 (0%)
Night sweats	9 (17%)	4 (8%)	3 (12%)	1(4%)
Cough	8 (15%)	0 (0%)	6 (23%)	0 (0%)
Abdominal pain	8 (15%)	0 (0%)	1 (4%)	1(4%)
Thrombocytopenia	8 (15%)	2 (4%)	1(4%)	1(4%)
Nasopharyngitis	8 (15%)	0 (0%)	1 (4%)	0 (0%)
Hyperuricaemia	7 (13%)	2 (4%)	0 (0%)	0 (0%)
Neutropenia	7 (13%)	2 (4%)	2 (8%)	1(4%)
Nausea	5 (9%)	1 (2%)	5 (19%)	0 (0%)
Anaemia	5 (9%)	1 (2%)	4 (15%)	3 (12%)
Weight loss	4 (8%)	0 (0%)	4 (15%)	0 (0%)
Tumour pain	4 (8%)	0 (0%)	4 (15%)	0 (0%)
Hypertension	4 (8%)	2 (4%)	1 (4%)	0 (0%)
Hyperkalemia	2 (4%)	2 (4%)	0 (0%)	0 (0%)

Frits van Rhee, Raymond S Wong, Nikhil Munshi, Jean-Francois Rossi, Xiao-Yan Ke, Alexander Fosså, David Simpson, Marcelo Capra, Ting Liu, Ruey Kuen Hsieh, Yeow Tee Goh, Jun Zhu, Seok-Goo Cho, Hanyun Ren, James Cavet, Rajesh Bandekar, Margaret Rothman, Thomas A Puchalski, Manjula Reddy, Helqi van de Velde, Jessica Vermeulen, Corey Casper



## Kaplan-Meier plot of time to durable symptomatic response




Network Hematological Diseases (ERN EuroBloodNet)

Network for rare or low prevalence complex diseases



Kaplan-Meier plot of time to next treatment in the intention-to-treat population during the masked treatment period




Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials

Frits van Rhee, Corey Casper, Peter M Voorhees, Luis E Fayad, Damilola Gibson, Karan Kanhai, Razelle Kurzrock www.thelancet.com/haematology Published online February 3, 2020

- Siltuximab treatment might falsely increase IL-6 concentrations for many months after the last dose
- siltuximab/IL-6 complexes <u>interfere with current</u>
   <u>immunological IL-6 quantification methods</u>
- Serum IL-6 concentrations should not be used to assess response to treatment.
- C-reactive protein has been identified as a surrogate biomarker for IL-6 activity, because its production by hepatocytes is fully dependent on IL-6 in vivo

### THE LANCET Haematology



# iMCD treatment

### Anti CD20 drugs

### Rituximab


- Rituximab (375 mg/m2 x 4-8 doses) recommend as a <u>first-line alternative to anti IL-6</u> <u>mAb therapy</u> for patients with nonsevere iMCD who do not have marked cytokine-driven symptomatology (Frits van Rhee, Blood, 2018).
- Rituximab recommendation based on <u>limited</u> <u>data set</u>, because rituximab has not been subjected to systematic study in iMCD and data are confined to case reports or small series
- Most papers report the <u>use of rituximab along</u> with conventional chemotherapies.



Network for rare or low prevalence complex diseases

Hematological Diseases (ERN EuroBloodNet)





#### Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Sheila K Pierson, MS, Yue Ren, Johnson Khor, Eric Haljasmaa, Jasira Ziglar, Katherine Floess, Erin NaPier, Faizaan Akhter, Amy Y Liu, Damilola Gibson, Karan Kanhai, MD PhD, Rabecka Martin, PhD, Amy Chadburn, MD, Gordan Srkalovic, MD PhD, Megan S. Lim, MD PhD, Corey Casper, MD MPH, Thomas S. Uldrick, MD MS, Elaine S. Jaffe, MD, Frits van Rhee, MD PhD, Hongzhe Lee, PhD, David C Fajgenbaum, MDMBA,MSc


- Among 37 expert-confirmed iMCD patients, we found:
  - 58% response (11/19) to regimens inclusive of siltuximab,
  - 47% (8/17) to those inclusive of tocilizumab,
  - 27% (7/26) to those inclusive of rituximab.
- Further, in these patients:
  - siltuximab±CS induced response in 11/16 (69%),
  - tocilizumab±CS induced response in 3/6 (50%),
  - rituximab±CS induced response in 1/6 (17%) patients.
- In this cohort Siltuximab and Tocilizumab demonstrated similar response.



Hematological Diseases (ERN EuroBloodNet)








### Epidemiology and treatment patterns of idiopathic multicentric Castleman **6** blood advances disease in the era of IL-6-directed therapy



Sudipto Mukherjee, Rabecka Martin,<sup>2</sup> Brenda Sande,<sup>2</sup> Jeremy S. Paige,<sup>3</sup> and David C. Fajgenbaum<sup>4</sup>

<sup>1</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; <sup>2</sup>EUSA Pharma, Burlington, MA; <sup>3</sup>Eversana, LLC, Milwaukee, WI; and <sup>4</sup>Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA



- Among patients with iMCD, corticosteroid monotherapy was the most commonly used treatment (39.0%), whereas 33.1% of patients had no
- Surprisingly, only **9.8% of patients received an IL-6–targeted therapy**
- Of a total of 170 patients with iMCD who received any therapy, 65.3% **received only a single therapeutic class** during the study period, whereas far fewer patients received 2 (24.4%) or 3 classes (9.5%).

Corticosteroid

Chemotherapy

Rituximab

Siltuximab




# **iMCD** – Other treatments



LYMPHOID NEOPLASIA | MAY 7, 2020

#### Increased mTOR activation in idiopathic multicentric Castleman disease

Daniel J. Arenas, Katherine Floess, Dale Kobrin, Ruth-Anne Langan Pai, Maya B. Srkalovic, Mark-Avery Tamakloe, Rozena Rasheed, Jasira Ziglar, Johnson Khor, Sophia A. T. Parente, Sheila K. Pierson, Daniel Martinez, Gerald B. Wertheim, Taku Kambayashi, Joseph Baur, David T. Teachey, David C. Fajgenbaum



#### Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

ClinicalTrials.gov Identifier: NCT03933904



Recruitment Status (): Recruiting First Posted 1: May 1, 2019 Last Update Posted (): November 18, 2021

# S blood

iropean ference

twork

6 Networ Hematological Diseases (ERN EuroBloodNet)

or rare or low prevalence complex diseases

CLINICAL TRIALS AND OBSERVATIONS | APRIL 18, 2019

#### Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease

#### U Clinical Trials & Observations

Lu Zhang, Ai-lin Zhao, Ming-hui Duan, Zhi-yuan Li, Xin-xin Cao, Jun Feng, Dao-bin Zhou, Ding-rong Zhong, David C. Fajgenbaum, Jian Li

### The TCP regimen administered for 2 years or until treatment failure.

- Thalidomide 100 mg daily for year 1 and year 2; ٠
- Oral cyclophosphamide 300 mg/m2 of a 4-٠ week cycle for year 1;
- Prednisone 1 mg/kg twice a week of a 4-week cycle for year 1

## **iMCD** case presentation

### Case diagnosis and treatment

- According to consensus diagnostic criteria, iMCD diagnosis was established.
- iMCD was classified as "nonsevere" (absence of compromised performance status, renal dysfunction, anasarca, severe anemia or pulmonary involvement).
- <u>Siltuximab (11 mg/kg every 3 weeks)</u> was started, with rapid improvement of systemic symptoms and laboratory parameters.
- Computed tomography (CT) scan after 6 months of anti-IL-6 therapy → <u>complete regression of all previously</u> <u>reported adenopathies</u>.
- As we report, patient is still receiving Siltuximab every 3 weeks maintaining a good clinical response.




Network or rare or low prevalence complex diseases

Diseases (ERN EuroBloodNet)



The	reported 50-years-old Caucasian male presented at diagnosis:
	Constitutional symptoms: night sweats, fever (>38°C), weight loss, or fatigue
sis	Elevated CRP (>10 mg/L) or ESR (>15 mm/h)
Diagnosis	Histopathologic lymph node features consistent with the iMCD spectrum
	Enlarged lymph nodes (≥ 1 cm in short-axis diameter) in ≥ 2 lymph node stations
iMCD	HIV and HHV8 negative
Ë	Elevated IL-6
	ECOG < 2
rity	No renal dysfunction
Severity	Neither anasarca or ascites or pleural/pericardial effusion
iMCD S	No severe anemia
Ξ	No pulmonary involvement










# POEMS syndrome vs iMCD



- 72 years old male
- Medical history: Obstructive sleep apnea treated with CPAP, secondary polycytemia treat with phlebotomy,
- Hospitalization (2021) for suspected lymphoproliferative disorder






# POEMS syndrome vs iMCD



- 72 years old male
  - Medical history: Obstructive sleep apnea treated with CPAP, secondary polycytemia treat with phlebotomy,
- Hospitalization (2021) for suspected lymphoproliferative disorder





## iMCD or not iMCD ?

	Inclusion diagnostic criteria for iMCD		,	
Medical history: breast fibroadenoma, recurrent	<ul> <li>I. Major Criteria (need both):</li> <li>1. Histopathologic lymph node features consistent with the iMCD spectrum</li> </ul>			
•				
Herpes simplex infections	2. Enlarged lymph nodes ( $\geq$ 1 cm in short-axis diameter) in $\geq$ 2 lymph node stations			
	II. Minor Criteria (need at least 2 of 11 criteria with at least 1 laboratory criterion)			
Herretelesis evaluation: Dilatoral avillant	Laboratory*			
ade <b>D</b> ath was in with wish with a set			Х	
Both major criteria without	es)	Х		
		unt > 400 k/mL)	Х	
		Х		
Axi		or > 10 mg/100 ml)	Х	
יאני	7	1700 mg/dL)	Х	
Diagnosis of iMCI	D is not possible		Х	
			Х	
Blo			Х	
5170/mm <sup>3</sup> , normal serum albumin, IgG 1175 mg/dL,	4. Eruptive cherry hemangiomatosis or violaceous papules		Х	
	5. Lymphocytic interstitial pneumonitis		Х	
CRP and ESR negative, no proteinuria,	Select additional features supportive of, but not required for diagnosis			
nost common viral infections (including HIV)	Elevated IL-6, sIL-2R, VEGF, IgA, IgE, LDH, and/or B2M		Х	
negative, normal IL-6 levels	Diagnosis of other disorders that have been associated with iMCD		Х	
European	Reticulin fibrosis of bone marrow (particularly in patients with TAFRO syndrome)			
Reference $\star$ $\star$	Wehina	rc		

Table 1. Diagnostic criteria for idiopathic multicentric Castleman disease (iMCD)



٠

etwork for rare or low prevalence complex diseases

3 Networ Hematological Diseases (ERN EuroBloodNet)





### **iMCD** case

Diseases (ERN EuroBloodNet)

• Medical history: Obesity, AF, glaucoma


 Table 1. Diagnostic criteria for idiopathic multicentric Castleman disease (iMCD)

 Inclusion diagnostic criteria for iMCD
 Image: Criteria (need both):

 1. Major Criteria (need both):
 Image: Criteria (need both):

 1. Histopathologic lymph node features consistent with the iMCD spectrum
 ✓

 2. Enlarged lymph nodes (≥ 1 cm in short-axis diameter) in ≥ 2 lymph node stations
 ✓















Network Hematological Diseases (ERN EuroBloodNet)

for rare or low prevalence complex diseases







# Thanks to....

my Castleman patients

Dr. Simone Ragaini for his precious assistance









for rare or low prevalence complex diseases





